194 related articles for article (PubMed ID: 32110525)
1. Dose escalation (81 Gy) with image-guided radiation therapy and volumetric-modulated arc therapy for localized prostate cancer: A retrospective preliminary result.
Huang SY; Wu CT; Liu DW; Wang TH; Liao YH; Chen YW; Hsu WL
Ci Ji Yi Xue Za Zhi; 2020; 32(1):75-81. PubMed ID: 32110525
[TBL] [Abstract][Full Text] [Related]
2. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
[TBL] [Abstract][Full Text] [Related]
4. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study.
Zilli T; Jorcano S; Rouzaud M; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escudé L; Mollà M; Linero D; Weber DC; Miralbell R
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):382-9. PubMed ID: 20884129
[TBL] [Abstract][Full Text] [Related]
5. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
6. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
[TBL] [Abstract][Full Text] [Related]
7. 11C choline PET guided salvage radiotherapy with volumetric modulation arc therapy and hypofractionation for recurrent prostate cancer after HIFU failure: preliminary results of tolerability and acute toxicity.
Alongi F; Liardo RL; Iftode C; Lopci E; Villa E; Comito T; Tozzi A; Navarria P; Ascolese AM; Mancosu P; Tomatis S; Bellorofonte C; Arturo C; Scorsetti M
Technol Cancer Res Treat; 2014 Oct; 13(5):395-401. PubMed ID: 24000995
[TBL] [Abstract][Full Text] [Related]
8. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients.
Zelefsky MJ; Fuks Z; Hunt M; Yamada Y; Marion C; Ling CC; Amols H; Venkatraman ES; Leibel SA
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1111-6. PubMed ID: 12128109
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
12. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
13. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
[TBL] [Abstract][Full Text] [Related]
14. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control.
Petrongari MG; Landoni V; Saracino B; Gomellini S; Arcangeli S; Iaccarino G; Pinnarò P; Arcangeli G; Strigari L
J Exp Clin Cancer Res; 2013 Dec; 32(1):103. PubMed ID: 24330467
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
[TBL] [Abstract][Full Text] [Related]
17. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
18. Image guided dose escalated prostate radiotherapy: still room to improve.
Martin JM; Bayley A; Bristow R; Chung P; Gospodarowicz M; Menard C; Milosevic M; Rosewall T; Warde PR; Catton CN
Radiat Oncol; 2009 Nov; 4():50. PubMed ID: 19887007
[TBL] [Abstract][Full Text] [Related]
19. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
20. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.
Kitamura K; Shirato H; Shinohara N; Harabayashi T; Onimaru R; Fujita K; Shimizu S; Nonomura K; Koyanagi T; Miyasaka K
Cancer J; 2003; 9(4):268-76. PubMed ID: 12967137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
